相关实验视频

Updated: Jun 7, 2025

A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance

A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance

Published on: October 19, 2018

用自组合溶液进行内静止的有效性和安全性在患有结肠分管出血的患者中:一个多中心试点研究 (附视频)

Daisuke Yamaguchi¹, Naoyuki Tominaga², Genki Mori³

¹Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Gastrointestinal endoscopy

|November 9, 2024

概括

普拉斯塔特 (PuraStat) 是一种新型的止血剂,在治疗结肠分管出血方面表现出100%的疗效. 与传统方法相比,它的使用显著降低了复发出血率.

科学领域:

胃肠病学胃肠病学
内镜血液静止症 (Endoscopic Hemostasis) 是一种内镜血液静止症.
生物材料是一种生物材料.

背景情况:

结肠分管出血 (CDB) 是下胃肠道出血的常见原因之一.
有效的内镜血液静止对于管理活性CDB至关重要.
普拉斯塔特 (PuraStat) 是一种自组装的基于的止血剂,为局部出血控制提供了一种新方法.

研究的目的:

评估PuraStat在CDB患者内镜血静的疗效和安全性.
为了比较基于PuraStat的血液静止与传统方法的结果.
为了确定影响CDB的内镜血液静止后复发出血的因素.

主要方法:

一项多中心试点研究涉及25名患有CDB和最近出血的耻辱痕迹的患者.
患者接受PuraStat单一治疗或结合治疗,包括内镜带绑定 (EBL) 或剪切 (A组).
结果与没有PuraStat治疗的历史队列 (B组) 进行了比较.

主要成果:

使用PuraStat进行内镜血静止的技术成功率为100% (25/25名患者).
与B组 (20.9%,P=0.047) 相比,A组 (4.0%) 在30天内复发出血明显较少.
多变量分析表明,PuraStat的添加减少了复发出血的风险 (OR=0.11,P=0.045).

结论:

普拉斯塔特是CBD常规内镜血液静止的有效和安全补充剂.
将PuraStat添加到标准治疗中可以显著降低复发性分分管出血的发生率.
普拉斯塔特提供了一种有希望的选择,用于改善结肠分管出血中的静血结果.

更多相关视频

The C-seal: A Biofragmentable Drain Protecting the Stapled Colorectal Anastomosis from Leakage

The C-seal: A Biofragmentable Drain Protecting the Stapled Colorectal Anastomosis from Leakage

Published on: November 4, 2010

Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model

Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model

Published on: August 11, 2018

相关概念视频

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...